NovaBay Pharmaceuticals, Inc.
NBYNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for NBY. That does not mean none is planned.
Get an email about NBY's next catalysts
Track NovaBay Pharmaceuticals (NBY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
WebsiteCD07223 Topical
Impetigo
NVC-422
Impetigo
Auriclosene
Bacterial Conjunctivitis
sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
Asymptomatic Bacteriuria
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CD07223 Topical | Phase 3 | Impetigo | - | - |
NVC-422 | Phase 2 | Impetigo | - | - |
Auriclosene | Phase 2 | Bacterial Conjunctivitis | - | - |
sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate | Phase 2 | Asymptomatic Bacteriuria | - | - |
Impetigo
3 drugs in this indication
Bacterial Conjunctivitis
2 drugs in this indication
Adenoviral Conjunctivitis
1 drug in this indication
Asymptomatic Bacteriuria
1 drug in this indication
Urinary Catheter Blockage and Encrustation
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in NovaBay Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in NovaBay Pharmaceuticals, Inc.'s (NBY) pipeline across Phase 3, Phase 2. Its lead program is CD07223 Topical (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is NovaBay Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for NovaBay Pharmaceuticals, Inc. (NBY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NBY biotech catalysts?→
Add NBY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow NovaBay Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.